Note from the editor
BioPharma Dive will not publish on Monday, Feb. 19, because the U.S. financial markets will close in observance of Presidents Day.
If you're looking to catch up on reading over the long weekend, check out BioPharma Dive's recent reports on Vivek Ramaswamy's continued faith in Roivant's model, or on pharma's growing interest in virtual reality marketing. Oh, and Bristol-Myers recently made a pretty big bet on Nektar Therapeutics' experimental cancer immunotherapy.
As always, feel free to reach out with any tips or questions. We'll be back in your inboxes Tuesday.
Best,
Ned Pagliarulo
Editor, BioPharma Dive
E-mail
Top news
Acquiring the tech unicorn will help Roche better use real-world evidence in the development of cancer drugs, while building its data analytics expertise.
|
Feature Story
A relatively large research collaboration could change the deal landscape. Elsewhere, the Alzheimer's development picture is getting a makeover.
|
Already approved in Europe, Vitaros didn't gain favor with U.S. regulators, who found CMC and safety issues with the erectile dysfunction drug.
|
In new guidance to industry, the regulator signaled greater flexibility around the use of biomarkers in studying the neurodegenerative disease.
|
Acquiring MPI Research should raise Charles Rivers' profits as early as this year and expand its business with biotech.
|
BROUGHT TO YOU BY – BIOVIA
Accelerating Life Science R&D with Digital Platforms
Life science CEOs are realizing a “digital transformation” is essential to financial success. Download this report featuring research from Gartner to learn about the future of Digital R&D.
What We're Reading
 Reuters
|
 Kaiser Health News
|
 CNN
|
 Financial Times
|
Upcoming Event
Dive Into a Topic
|
